Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

Based in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

Roivant's high valuation is justified, with a strong cash position, promising drug pipeline, and strategic partnerships ...

After hours: October 22 at 7:58 PM EDT ...

Looking at options history for Moderna MRNA we detected 21 trades. If we consider the specifics of each trade, it is accurate ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Social media users are spreading new levels of misinformation based on discredited claims that nanobots are lurking in ...